MedPath

NICE Reverses Decision, Approves Sobi's Altuvoct for Hemophilia A Treatment in England

• England's NICE has reversed its initial rejection of Altuvoct, Sobi's once-weekly treatment for severe hemophilia A, following the submission of additional evidence.

• The positive reimbursement decision marks a significant expansion of treatment options for hemophilia A patients in England, joining approvals in two other European countries.

• Altuvoct's approval demonstrates the impact of supplementary evidence in health technology assessment processes, potentially setting a precedent for future drug evaluations.

In a significant policy reversal, England's National Institute for Health and Care Excellence (NICE) has approved Sobi's Altuvoct for reimbursement, expanding treatment options for patients with severe hemophilia A. The decision comes after the agency's initial rejection was overturned following the submission of additional supporting evidence.
The once-weekly treatment, developed by Swedish Orphan Biovitrum (Sobi), is now authorized for both prevention and treatment of bleeding episodes in patients with severe hemophilia A. This approval marks the third European country to provide reimbursement coverage for Altuvoct, signifying growing acceptance of the therapy in major healthcare markets.

Clinical Impact and Treatment Profile

Altuvoct represents an important addition to the hemophilia A treatment landscape, offering patients a once-weekly dosing schedule that could potentially improve treatment adherence compared to more frequently administered alternatives. The therapy is designed to replace the missing or defective Factor VIII protein essential for proper blood clotting in hemophilia A patients.

Market Access Journey

The path to reimbursement approval in England highlights the evolving nature of health technology assessment processes. NICE's willingness to reconsider its initial position based on additional evidence demonstrates the importance of comprehensive data submission in securing market access for innovative therapies.

Healthcare System Integration

The positive reimbursement decision is expected to have significant implications for hemophilia A management within England's National Health Service (NHS). Healthcare providers will now have access to an additional treatment option that could potentially offer benefits in terms of administration frequency and patient compliance.
The approval of Altuvoct adds to the growing arsenal of treatments available to clinicians managing patients with severe hemophilia A, potentially offering new opportunities to optimize individual treatment approaches based on patient needs and preferences.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Pfizer's Gene Therapy Fidanacogene Elaparvovec Shows Promise in Haemophilia B Treatment

Pfizer's fidanacogene elaparvovec (SPK-9001) gene therapy met its primary endpoint in the Phase 3 BENEGENE-2 study for haemophilia B, demonstrating non-inferiority and superiority in annualized bleeding rate.
The BENEGENE-2 study showed a 71% reduction in annualized bleeding rate (ABR) with fidanacogene elaparvovec compared to the pre-treatment period in adult males with moderately severe to severe haemophilia B.

BMS's Sotyktu Demonstrates Success in Phase III Psoriatic Arthritis Trials

Bristol Myers Squibb's Sotyktu has achieved positive results in two Phase III clinical trials for psoriatic arthritis, marking a significant advancement in treatment options for this chronic inflammatory condition. This development expands the potential therapeutic applications of Sotyktu beyond its existing indications.

EMA Validates Application for Less Frequent Elfabrio Dosing in Fabry Disease

The EMA has validated an application for a less frequent Elfabrio (pegunigalsidase alfa) regimen for Fabry disease, potentially reducing treatment burden.
The proposed regimen involves administering Elfabrio every four weeks at 2 mg/kg, compared to the current bi-weekly regimen of 1 mg/kg.

UK First in Europe to Reimburse Tirzepatide for Obesity Treatment

The UK's NICE has approved reimbursement for tirzepatide (Mounjaro) for obesity, making it the first European country to do so, based on its superior weight loss efficacy compared to semaglutide.
NICE stipulates that reimbursement will initially prioritize patients with a BMI of 35 or higher and at least one comorbidity, with a managed rollout to ensure healthcare professionals can meet all patient needs.

EU Approves Pfizer's Hympavzi for Hemophilia A and B

The European Commission has granted marketing authorization for Pfizer's Hympavzi (marstacimab) for hemophilia A and B patients aged 12 and older.
Hympavzi is a once-weekly prophylactic treatment to reduce bleeding episodes in patients without inhibitors to Factor VIII (FVIII) or Factor IX (FIX).

EU Approves Pfizer's Hympavzi for Severe Hemophilia A and B

The European Commission has granted marketing authorization for Hympavzi, a new treatment developed by Pfizer.
Hympavzi is indicated for severe hemophilia A or B in both adult and adolescent patients without inhibitors.

European Commission Approves Pfizer's HYMPAVZI for Hemophilia A and B

The European Commission has granted marketing authorization to Pfizer's HYMPAVZI (marstacimab) for treating hemophilia A and B based on Phase 3 trial results.
HYMPAVZI is the first once-weekly, subcutaneous treatment in the EU for severe hemophilia B and can be administered via a pre-filled, auto-injector pen.

European Committee Recommends Approval of Lecanemab for Early Alzheimer's

The European Medicines Agency's committee has recommended the approval of lecanemab for treating early Alzheimer's disease, reversing its previous rejection.
Lecanemab, co-developed by Eisai and Biogen, targets and clears amyloid plaques in the brain, associated with slowing cognitive decline in Alzheimer's patients.

EU Backs Eisai's Leqembi for Alzheimer's in Reversal of Earlier Rejection

The European Medicines Agency's advisory panel has reversed its initial negative decision and now supports the use of Eisai's Leqembi for treating Alzheimer's disease.
Leqembi's use will be restricted to patients with one or no copy of the ApoE4 gene variant due to the increased risk of brain swelling and bleeding in those with two copies.

Fidanacogene Elaparvovec Demonstrates Strong Efficacy in Hemophilia B Gene Therapy Trial

Fidanacogene elaparvovec gene therapy significantly reduces bleeding episodes in hemophilia B patients compared to baseline.
The Phase 3 open-label study showed a substantial decrease in annualized bleeding rates post-therapy with stable factor IX activity.

Reference News

[1]
Additional Evidence Persuades England To Reimburse Hemophilia Drug Altuvoct
insights.citeline.com · Feb 28, 2025
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy